by Lauren Chase Biosimilars have made a lot of headway in the pharmaceutical world over the past few years. While they’ve been hailed for their cost-saving potential, many have failed to take hold in the U.S. market. Leaders in healthcare have claimed that the regulatory systems in place will make biosimilars too expensive to continue...
by University of Minnesota Biologics used to treat patients can be incredibly expensive, so there was significant hope that biosimilar drugs—which are highly similar to an existing biologic drug on the market—could serve as a less-costly substitute. However, new research from the University of Minnesota and Mayo Clinic finds that while physicians are indeed willing to prescribe these drugs, the...
